Priebe Waldemar 4
4 · CNS Pharmaceuticals, Inc. · Filed Aug 1, 2023
Insider Transaction Report
Form 4
Priebe Waldemar
10% Owner
Transactions
- Sale
Common Stock
2023-03-20$1.08/sh−5,000$5,400→ 196,807 total(indirect: See footnote) - Sale
Common Stock
2022-12-08$2.40/sh−5,500$13,200→ 234,605 total(indirect: See footnote) - Sale
Common Stock
2023-03-15$1.22/sh−5,000$6,100→ 211,807 total(indirect: See footnote) - Sale
Common Stock
2023-03-17$1.13/sh−5,000$5,650→ 201,807 total(indirect: See footnote) - Sale
Common Stock
2023-03-22$1.08/sh−5,000$5,400→ 186,807 total(indirect: See footnote) - Sale
Common Stock
2023-03-28$1.04/sh−10,000$10,400→ 156,807 total(indirect: See footnote) - Sale
Common Stock
2023-03-24$1.08/sh−5,000$5,400→ 171,807 total(indirect: See footnote) - Sale
Common Stock
2022-12-09$2.43/sh−2,798$6,799→ 231,807 total(indirect: See footnote) - Sale
Common Stock
2023-03-13$1.30/sh−5,000$6,500→ 221,807 total(indirect: See footnote) - Sale
Common Stock
2022-12-06$2.47/sh−5,500$13,585→ 245,605 total(indirect: See footnote) - Sale
Common Stock
2023-03-10$1.29/sh−5,000$6,450→ 226,807 total(indirect: See footnote) - Sale
Common Stock
2023-03-14$1.35/sh−5,000$6,750→ 216,807 total(indirect: See footnote) - Sale
Common Stock
2023-03-16$1.24/sh−5,000$6,200→ 206,807 total(indirect: See footnote) - Sale
Common Stock
2023-03-27$1.09/sh−5,000$5,450→ 166,807 total(indirect: See footnote) - Sale
Common Stock
2022-12-07$2.46/sh−5,500$13,530→ 240,105 total(indirect: See footnote) - Sale
Common Stock
2023-03-23$1.08/sh−10,000$10,800→ 176,807 total(indirect: See footnote) - Sale
Common Stock
2023-03-21$1.10/sh−5,000$5,500→ 191,807 total(indirect: See footnote)
Footnotes (1)
- [F1]Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc.